Table 1 Baseline characteristics of the study population (n = 74)
Variables | Placebo NÂ =Â 38 | n-3 PUFAs NÂ =Â 36 |
|---|---|---|
Age (years) | 66.7 (±6.8) | 64.4 (±6.7) |
Female sex, n (%) | 12 (31.6) | 14 (38.9) |
Hypertension, n (%) | 36 (93.7) | 36 (100) |
Hyperlipidemia, n (%) | 22 (57.9) | 28 (77.8) |
Metabolic syndrome, n (%) | 38 (100) | 36 (100) |
Obesity, n (%) | 25 (65.8) | 23 (63.9) |
Waist circumference (cm) | 107 (98; 113) | 106 (99; 112) |
Body mass index (kg/m2) | 31.1 (28.1; 32.7) | 30.9 (27.9; 34.7) |
Body fat (%) | 30.4 (27.4; 35.8) | 34.0 (31.0; 43.0) |
Visceral fat (%) | 15.74 (±4.9) | 16.25 (±4.5) |
Total body water (%) | 47.9 (43.9; 49.8) | 47.5 (44.2; 49.2) |
Muscle mass (kg) | 53.5 (±11.5) | 56.85 (±9.2) |
DM2 duration (years) | 10 (6; 15) | 10 (6.5; 15) |
CAD, n (%) | 38 (100) | 36 (100) |
PAD, n (%) | 14 (38.9) | 12 (31.3) |
Previous MI, n (%) | 16 (42.1) | 12 (33.3) |
Previous PCI, n (%) | 25 (65.8) | 22 (61.1) |
Creatinine (μmol/L) | 84 (66; 94) | 86.5 (74; 100) |
eGFR (MDRD) (mL/min/1.73Â m2) | 78.6 (70; 90) | 78 (69; 89) |
Treatment, n (%) | ||
 Beta blocker | 31 (81.6) | 30 (83.3) |
 ACEI or ARB | 33 (86.8) | 34 (94.4) |
 Long acting nitrate | 5 (13.2) | 6 (16.7) |
 Calcium antagonist | 13 (34.2) | 19 (52.8) |
 Statin | 33 (86.8) | 35 (97.2) |
 Fibrate | 0 | 1 (2.78) |
 ASA | 38 (100) | 36 (100) |
 Clopidogrel | 19 (50) | 14 (38.9) |
 Metformin | 24 (63.2) | 25 (69.4) |
 Sulfonylurea | 14 (36.8) | 17 (47.2) |
 Acarbose | 1 (2.6) | 2 (5.6) |
 DPP-IV | 1 (2.6) | 0 |
 Insulin | 16 (42.1) | 16 (44.4) |
 PPI | 10 (26.3) | 12 (33.3) |
 Loop diuretic | 6 (15.8) | 3 (8.3) |
 Diuretic | 11 (28.9) | 11 (30.6) |
 AA | 6 (15.8) | 3 (8.3) |